During its policy committee meetings, PMC members debate and establish the Coalition's policy priorities and positions. These meetings frequently feature policy leaders, including representatives from the U.S. Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), and Congressional staffers, as guest speakers.
For questions about PMC's policy committee meetings, please contact David Davenport, Manager, Public Policy & Secretary to the Board.
June 29, 2020
Defining Priorities for the Field Against the Backdrop of COVID-19
During the business meeting, PMC members will discuss their latest advocacy and evidence development activities to advance personalized medicine against the backdrop of the COVID-19 pandemic.
In addition to sharing our thoughts on how the COVID-19 pandemic will impact personalized medicine, we will share updates on responding to U.S. Reps Diana DeGette (D-CO) and Fred Upton (R-MI)'s 21st Century Cures 2.0 Concept Paper, advocating for improved reimbursement pathways for chimeric antigen receptor (CAR)T-cell therapies, and advancing PMC's research program and sponsorship opportunities supporting the study of the clinical and economic utility of personalized medicine in multiple disease states, including PMC's initiative to understand genomic testing utilization and coverage in the U.S.
September 24, 2020; 12:00 - 2:00 p.m. ET
December 10, 2020; 12:00 - 2:00 p.m. ET
May 7, 2020
Personalized Medicine in the Era of COVID-19
During the business meeting, PMC members discussed their latest advocacy and evidence development activities to advance personalized medicine against the backdrop of the COVID-19 pandemic. Given the exigencies of the moment, the meeting was held virtually and shortened to one hour.
In addition to sharing thoughts on how the COVID-19 pandemic would impact personalized medicine, we discussed our efforts to recruit additional members for the Congressional Personalized Medicine Caucus, advocate for improved reimbursement pathways for chimeric antigen receptor (CAR) T-cell therapy and advance PMC's Research Program Studying the Clinical and Economic Utility of Personalized Medicine in Multiple Disease States.
Prior to the meeting, we encouraged review of the following summary from February's month's meeting - Action Items: A Meeting of PMC's Public and Science Policy Committees (February 27, 2020).
February 27, 2020
featuring staff from the offices of the Congressional co-chairs of the new bicameral, bipartisan Personalized Medicine Caucus
Staff from the offices of the Congressional co-chairs of the new bicameral, bipartisan Personalized Medicine Caucus joined the meeting of PMC's Public and Science Policy Committees on February 27 to discuss their respective members' interests in personalized medicine and the caucus' introductory briefing on the benefits of earlier detection, targeted treatment, and improved prevention strategies, which was scheduled for February 26. Our featured speakers during the committee meeting included Adeola Adesina, Legislative Assistant, Office of Rep. Eric Swalwell (CA-15) and Catherine Lenz, Legislative Assistant, Office of Rep. Tom Emmer (MN-06).
During a business meeting following the conversation with Adesina and Lenz, PMC members discussed the latest policy developments impacting personalized medicine including, recruiting members of Congress to join the Congressional Personalized Medicine Caucus, PMC’s ongoing and proposed evidence development projects and sponsorship opportunities, PMC’s activities in pharmacogenomics, the Verifying Accurate Leading-edge IVCT Development (VALID) Act and H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act.